Dr. Umar

This study shows how microbiome-derived IS and PCS drive renal fibrosis by activating the renal renin–angiotensin–aldosterone system associated epithelial-to-mesenchymal transition, amplifying TGF-β/Smad signaling and EMT features, and how losartan reduces this toxin-induced injury

Early diabetes complications dramatically increased five-year dialysis risk, with severity measured by DCSI strongly predicting renal decline.

What was reviewed? End-stage renal disease microbiome is framed in this StatPearls narrative review as the clinical endpoint of chronic kidney disease, integrating guideline-based staging, epidemiology, complications, and management. The chapter summarizes KDIGO criteria, registry data on ESRD burden, and guidance on renal replacement preparation. Although the review does not profile gut or oral microbial […]

This study shows how a toxic gut microbiome enriched in uraemic toxin-producing species drives CKD progression, validated across cohorts and animal models, with diet emerging as a modifiable factor.

Gut microbiome dysbiosis precedes kidney transplant rejection, marked by loss of SCFA-producing taxa, reduced diversity, and enrichment of disease-associated bacteria. This prerejection signature reflects a prolonged CKD-like state and may serve as an early biomarker and therapeutic target.

CKD increases blood lead and cadmium concentrations while reducing urinary elimination, heightening susceptibility to heavy metal toxicity in CKD, with disproportionately greater effects in Black Americans.

This study examines microbiota in pediatric ESRD, revealing dysbiosis, reduced diversity, and elevated uremic toxins shaped by dialysis modality and transplantation, defining key microbial signatures.

Hemodialysis patients showed higher caries burden and a marked shift toward acidogenic, aciduric supragingival microbiota, including elevated S. mutans and Lactobacillus species, indicating heightened caries vulnerability despite increased salivary pH and urea.

This study identifies major gut microbiota alterations in CKD, especially severe loss of Akkermansia, and links these shifts to inflammatory cytokines, suggesting key microbial signatures relevant to CKD progression.

This pilot study identified reduced microbial diversity and a Proteobacteria-enriched blood microbiome profile in CKD, with microbial shifts correlating to kidney function, suggesting potential biomarker value.

This study identifies distinct gut microbiota alterations in CKD and highlights microbial biomarkers—including Lachnospira and Ruminococcus gnavus—that discriminate disease status and track progression toward hemodialysis.

This study mapped gut microbiome disruptions across CKD stages, identifying diagnostic microbial signatures, enriched toxin-producing taxa, depleted beneficial genera, and strong links between microbes and renal biomarkers.

This study identified a distinct microbial signature in stage 4–5 CKD marked by loss of SCFA-producing commensals and expansion of Proteobacteria, linking gut dysbiosis to uremic toxin accumulation and systemic inflammation.

Early CKD shows reduced SCFA-producing species and altered microbial metabolic pathways despite stable overall diversity, indicating subtle but clinically relevant microbiome disruption.

Pediatric CKD is marked by gut dysbiosis, impaired barrier function, and microbial metabolite shifts—especially elevated indoxyl sulfate—that activate inflammatory pathways, reshape monocyte and T-cell phenotypes, and contribute to chronic systemic inflammation.

This study integrates long-read microbiome profiling with untargeted metabolomics to characterize distinct dysbiosis and metabolite alterations across diabetic, hypertensive, and non-comorbid CKD. The findings reveal robust species–metabolite networks that differentiate CKD subtypes with high diagnostic performance, underscoring their potential as early biomarkers of renal dysfunction and etiologically specific pathophysiology.

This study shows that diet strongly alters gut microbiota in CKD, with low-protein, high-fiber intake enhancing SCFA-producing bacteria and reducing TMAO and inflammation.

Bacteria regulate transition metal levels through complex mechanisms to ensure survival and adaptability, influencing both their physiology and the development of antimicrobial strategies.

This study links low-level heavy metal exposure to increased CKD risk and higher cadmium-associated mortality, with synergistic toxicity when both metals are elevated.

The study demonstrates that arsenic exposure is independently associated with CKDu in central India, with CKDu and CKD patients showing heavier burdens of cadmium, lead, and chromium than healthy individuals.

Study of chronic kidney disease microbiome resistance showing metal–antibiotic co-resistance, early-stage enrichment of Firmicutes/Proteobacteria, and progressive loss of resistance genes as CKD advances.

This study analyzed how low-level heavy metal exposures influence CKD risk and identified α-klotho as a mechanistic mediator, highlighting cadmium’s nephrotoxicity and complex mixture effects.

This study evaluated how serum uric acid levels relate to infection outcomes in ICU patients and found that uric acid reflects renal and metabolic stress rather than prognosis.

Serum zinc levels decreased with worsening diabetic kidney disease, especially with macroalbuminuria, linking zinc deficiency to nutritional decline, sarcopenia, oxidative stress, and potential microbiome shifts influencing disease progression.